136 related articles for article (PubMed ID: 9671952)
1. Clinical usefulness of CA-19-9 in pancreatic carcinoma.
Nakao A; Oshima K; Nomoto S; Takeda S; Kaneko T; Ichihara T; Kurokawa T; Nonami T; Takagi H
Semin Surg Oncol; 1998; 15(1):15-22. PubMed ID: 9671952
[TBL] [Abstract][Full Text] [Related]
2. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
3. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
[TBL] [Abstract][Full Text] [Related]
4. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
6. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas.
Montgomery RC; Hoffman JP; Riley LB; Rogatko A; Ridge JA; Eisenberg BL
Ann Surg Oncol; 1997; 4(7):551-6. PubMed ID: 9367020
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of carcinoembryonic antigen and carbohydrate antigen 19-9 in stage IV colorectal cancer patients after R0 resection.
Abe S; Kawai K; Ishihara S; Nozawa H; Hata K; Kiyomatsu T; Tanaka T; Watanabe T
J Surg Res; 2016 Oct; 205(2):384-392. PubMed ID: 27664887
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer.
Ychou M; Duffour J; Kramar A; Gourgou S; Grenier J
Dis Markers; 2000; 16(3-4):105-10. PubMed ID: 11381189
[TBL] [Abstract][Full Text] [Related]
10. Clinical value and impact on prognosis of peri-operative CA 19-9 serum levels in stage I and II adenocarcinoma of the pancreas.
Piagnerelli R; Marrelli D; Roviello G; Ferrara F; Di Mare G; Voglino C; Petrioli R; Marini M; Macchiarelli R; Roviello F
Tumour Biol; 2016 Feb; 37(2):1959-66. PubMed ID: 26334620
[TBL] [Abstract][Full Text] [Related]
11. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
12. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma.
Chang JC; Kundranda M
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28335509
[TBL] [Abstract][Full Text] [Related]
13. Doubling time of serum CA 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis.
Nishida K; Kaneko T; Yoneda M; Nakagawa S; Ishikawa T; Yamane E; Nishioka B; Miyamoto Y; Takano H; Yoshikawa T; Kondo M
J Surg Oncol; 1999 Jul; 71(3):140-6. PubMed ID: 10404129
[TBL] [Abstract][Full Text] [Related]
14. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
[TBL] [Abstract][Full Text] [Related]
15. Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma.
Lee KJ; Yi SW; Chung MJ; Park SW; Song SY; Chung JB; Park JY
Yonsei Med J; 2013 May; 54(3):643-9. PubMed ID: 23549809
[TBL] [Abstract][Full Text] [Related]
16. A prognostic value of CA 19-9 but not of CEA in patients with gastric cancer.
Victorzon M; Haglund C; Lundin J; Roberts PJ
Eur J Surg Oncol; 1995 Aug; 21(4):379-84. PubMed ID: 7664902
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.
Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Arigami T; Mori S; Ueno S; Shinchi H; Takao S; Natsugoe S
Pancreatology; 2016; 16(6):1051-1056. PubMed ID: 27693096
[TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of preoperative serum CA 19-9 in patients with resectable gastric carcinoma: comparison with CEA.
Duraker N; Celik AN
J Surg Oncol; 2001 Apr; 76(4):266-71. PubMed ID: 11320518
[TBL] [Abstract][Full Text] [Related]
19. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
Tsavaris N; Kosmas C; Papadoniou N; Kopterides P; Tsigritis K; Dokou A; Sarantonis J; Skopelitis H; Tzivras M; Gennatas K; Polyzos A; Papastratis G; Karatzas G; Papalambros A
J Chemother; 2009 Dec; 21(6):673-80. PubMed ID: 20071292
[TBL] [Abstract][Full Text] [Related]
20. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]